Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
GKOS · NYSE · United States · Surgical & Medical Instruments & Apparatus
In shortGLAUKOS Corp is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -39.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -37.0% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -26.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.69× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -43.06× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.74 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -4.4% | 2/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 15.0% | 56/100 |
| Operating margin volatility | 11.9% | 1/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 21.5% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 294 | 283 | 315 | 383 | 507 |
| Cost of revenue | 67 | 69 | 76 | 94 | 112 |
| Gross profit | 227 | 214 | 239 | 289 | 283 |
| Research & development | 101 | 123 | 139 | 136 | 151 |
| Selling, general & admin | 179 | 193 | 224 | 261 | 332 |
| Operating income | (33) | (82) | (129) | (122) | (200) |
| Interest expense | 13 | 14 | 14 | 10 | 4.6 |
| Pre-tax income | (49) | (98) | (134) | (146) | (193) |
| Income tax | 0.3 | 0.8 | 0.9 | 0.8 | (5.4) |
| Net income | (50) | (99) | (135) | (146) | (188) |
| Diluted EPS | −$1.07 | −$2.09 | −$2.78 | −$2.77 | −$3.28 |
| Diluted shares (millions) | 46 | 47 | 48 | 53 | 57 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of GLAUKOS Corp are included in the Investor plan. Try free for 7 days →
0.74 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 29, 2026